RT Journal Article SR Electronic T1 Long-term treatment of patients with idiopathic pulmonary fibrosis with nintedanib: results from the TOMORROW trial and its open-label extension JF Thorax JO Thorax FD BMJ Publishing Group Ltd and British Thoracic Society SP 581 OP 583 DO 10.1136/thoraxjnl-2016-209701 VO 73 IS 6 A1 Luca Richeldi A1 Michael Kreuter A1 Moisés Selman A1 Bruno Crestani A1 Anne-Marie Kirsten A1 Wim A Wuyts A1 Zuojun Xu A1 Katell Bernois A1 Susanne Stowasser A1 Manuel Quaresma A1 Ulrich Costabel YR 2018 UL http://thorax.bmj.com/content/73/6/581.abstract AB The TOMORROW trial of nintedanib comprised a randomised, placebo-controlled, 52-week period followed by a further blinded treatment period and an open-label extension. We assessed outcomes across these periods in patients randomised to nintedanib 150 mg twice daily or placebo at the start of TOMORROW. The annual rate of decline in FVC was −125.4 mL/year (95% CI −168.1 to −82.7) in the nintedanib group and −189.7 mL/year (95% CI −229.8 to −149.6) in the comparator group. The adverse event profile of nintedanib remained consistent throughout the studies. These results support a benefit of nintedanib on slowing progression of idiopathic pulmonary fibrosis beyond 52 weeks.